Novo Nordisk A/S(NVO) Stock Research - Grey Stern Research

Novo Nordisk A/S (NVO) Stock Analysis

$109.20 (0.49%)

NVO Financial Performance


Use the table below to view Novo Nordisk A/S's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $109.20 -
52 Week Low $94.73 -
52 Week High $148.15 -
Market Cap $478.4 Billion 1/21
Gross Margin 84% 12/21
Profit Margin 38% 3/21
EBITDA margin 52% 2/21
Q3 - 2024 Revenue $10.5 Billion 2/21
Q3 - 2024 Earnings $4.0 Billion 2/21
Q3 - 2024 Free Cash Flow $4.6 Billion 2/21
Trailing 4 Quarters Revenue $39.9 Billion 2/21
Trailing 4 Quarters Earnings $14.0 Billion 2/21
Quarterly Earnings Growth 21% 12/21
Annual Earnings Growth 17% 11/21
Quarterly Revenue Growth 21% 9/21
Annual Revenue Growth 22% 7/21
Cash On Hand $8.4 Billion 3/21
Short Term Debt $814.2 Million 1/21
Long Term Debt $7.6 Billion 2/21

Novo Nordisk A/S Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Novo Nordisk A/S's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 34.25 2/21
PS 81.28 3/21
PB 26.91 4/21
PC 56.89 4/21
Liabilities to Equity 2.30 4/21
ROA 0.04 3/21
ROE 0.12 5/21
Current Ratio 1.44 16/21
Quick Ratio 0.27 21/21
Long Term Debt to Equity 0.43 6/21
Debt to Equity 0.47 6/21
Burn Rate -96.87 21/21
Cash to Cap 0.02 17/21
CCR 1.15 6/21
EV to EBITDA 1.89 6/21
EV to Revenue 1.77 15/21

Company Details

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

CEO: Mr. Lars Fruergaard Jrgensen

Website: https://www.novonordisk.com

Address: Novo Alle Bagsvaerd,

Exchange: New York Stock Exchange

Industry: Biotechnology

Novo Nordisk A/S Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Novo Nordisk A/S. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Novavax, Inc. NVAX $1.3 Billion
Vertex Pharmaceuticals Incorporated VRTX $117.7 Billion
Alnylam Pharmaceuticals, Inc. ALNY $32.5 Billion
BioMarin Pharmaceutical Inc. BMRN $12.0 Billion
Regeneron Pharmaceuticals, Inc. REGN $81.0 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
TG Therapeutics, Inc. TGTX $5.2 Billion
Sarepta Therapeutics, Inc. SRPT $12.0 Billion
Seagen Inc. SGEN $43.2 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Madrigal Pharmaceuticals, Inc. MDGL $7.0 Billion
Intellia Therapeutics, Inc. NTLA $1.5 Billion
CRISPR Therapeutics AG CRSP $4.4 Billion
CohBar, Inc. CWBR $1.4 Million
Hepion Pharmaceuticals, Inc. HEPA $4.2 Million
Moderna, Inc. MRNA $16.4 Billion
BioNTech SE BNTX $27.7 Billion
CureVac N.V. CVAC $639.3 Million
Terns Pharmaceuticals, Inc. TERN $540.2 Million
Ginkgo Bioworks Holdings, Inc. DNA $559.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
NVO Income Statements
Quarter Year Revenue Earnings
Q3 2024 Kr. 71.3 Billion Kr.27.3 Billion
Q2 2024 Kr. 68.1 Billion Kr.20.1 Billion
Q1 2024 Kr. 65.3 Billion Kr.25.4 Billion
Q4 2023 Kr. 65.9 Billion Kr.22.0 Billion
Q3 2023 Kr. 58.7 Billion Kr.22.5 Billion
Q2 2023 Kr. 54.3 Billion Kr.19.4 Billion
Q1 2023 $ 53.4 Billion $19.8 Billion
Q4 2022 Kr. 48.1 Billion Kr.13.6 Billion

View All

NVO Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 Kr.57.0 Billion Kr.397.4 Billion Kr.57.0 Billion Kr.120.5 Billion
Q2 2024 Kr.52.8 Billion Kr.369.4 Billion Kr.57.1 Billion Kr.112.5 Billion
Q1 2024 Kr.6.3 Billion Kr.298.9 Billion Kr.26.9 Billion Kr.98.9 Billion
Q4 2023 Kr.14.4 Billion Kr.314.5 Billion Kr.27.0 Billion Kr.106.6 Billion
Q3 2023 Kr.30.1 Billion Kr.300.1 Billion Kr.26.5 Billion Kr.93.0 Billion
Q2 2023 Kr.21.6 Billion Kr.280.8 Billion Kr.25.7 Billion Kr.90.5 Billion
Q1 2023 $14.9 Billion $250.0 Billion $25.5 Billion $79.9 Billion
Q4 2022 Kr.12.7 Billion Kr.241.3 Billion Kr.25.8 Billion Kr.83.5 Billion

View All

NVO Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 Kr.31.3 Billion -Kr.12.5 Billion Kr.4.2 Billion
Q2 2024 Kr.37.3 Billion -Kr.13.2 Billion Kr.46.5 Billion
Q1 2024 Kr.5.3 Billion -Kr.9.0 Billion -Kr.8.1 Billion
Q4 2023 -Kr.6.9 Billion -Kr.16.4 Billion -Kr.15.5 Billion
Q3 2023 Kr.30.3 Billion -Kr.10.6 Billion Kr.8.3 Billion
Q2 2023 Kr.21.5 Billion -Kr.7.0 Billion Kr.6.6 Billion
Q1 2023 Kr.25.0 Billion -Kr.4.8 Billion Kr.2.3 Billion
Q4 2022 Kr.928.0 Million -Kr.6.2 Billion -Kr.15.3 Billion

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions